Ensysce Biosciences(ENSC.US)

Company Encyclopedia
View More
name
Ensysce Biosciences
ENSC.US
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc.
1.906 T
ENSC.USMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking332/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-270.54%E
    • Profit Margin-244.49%E
    • Gross Margin-499.25%E
  • Growth ScoreD
    • Revenue YoY1.51%C
    • Net Profit YoY-38.42%D
    • Total Assets YoY-66.12%E
    • Net Assets YoY-86.71%E
  • Cash ScoreD
    • Cash Flow Margin-40.90%D
    • OCF YoY1.51%C
  • Operating ScoreB
    • Turnover0.71B
  • Debt ScoreD
    • Gearing Ratio72.49%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ensysce Biosciences Launches Phase 3 Trial of Abuse-Resistant Opioid PF614

    Ensysce Biosciences Inc. has initiated a Phase 3 clinical trial for PF614, an opioid designed for pain management with abuse protection. The first patient has been enrolled, and results will be available in the future. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    ENSC
    -0.55%
    Reuters·
    US
    ENSC
    -0.55%

    Ensysce Biosciences Secures New U.S. Patent for MPAR® Overdose Protection Technology, Extending Coverage Through 2042

    Ensysce Biosciences Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its MPAR® (Multi-Pill Abuse Resistance) technology. The patent extends protection through 2042 and includes composition-of-matter and method-of-use claims. MPAR® technology is designed to provide overdose protection by moderating opioid release when taken in excess. This news was originally published by Ensysce Biosciences Inc. via ACCESS Newswire on December 02, 2025.

    Reuters·
    US
    ENSC
    -0.55%
    Reuters·
    US
    ENSC
    -0.55%

    Ensysce Biosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting

    Ensysce Biosciences Inc. will hold its Annual Stockholders Meeting virtually on December 23, 2025, to discuss proposals outlined in the proxy statement. The announcement was made via EDGAR on November 21, 2025.

    Reuters·
    US
    ENSC
    -0.55%
    Reuters·
    US
    ENSC
    -0.55%

    Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

    Ensysce Biosciences received positive feedback from the FDA on its manufacturing approach for PF614, streamlining its path to commercial production. The FDA agreed with Ensysce's plans, allowing the company to proceed with manufacturing in partnership with Purisys, LLC. This milestone accelerates PF614's market entry, offering safer pain relief options. Ensysce's CEO, Dr. Lynn Kirkpatrick, expressed satisfaction with the FDA's alignment with their production requirements.

    Acceswire·
    US
    ENSC
    -0.55%
    Acceswire·
    US
    ENSC
    -0.55%

    Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

    Ensysce Biosciences has secured $4 million in convertible preferred stock financing, with potential for an additional $16 million over 24 months. This funding will accelerate the Phase 3 clinical development of PF614, a novel analgesic, and support corporate initiatives. The financing reflects strong investor confidence in Ensysce's mission to develop abuse- and overdose-resistant pain treatments. The company aims to complete Phase 3 trials within 18-24 months, moving closer to offering safer pain management solutions.

    Acceswire·
    US
    ENSC
    -0.55%
    Acceswire·
    US
    ENSC
    -0.55%
    © 2025 Longbridge｜Disclaimer